News and Announcements
Invigor Group acquires Sprooki for $10 million
- Published April 27, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Business intelligence and big data solutions company, Invigor Group, has acquired Singapore-based shopper engagement and analytics app Sprooki for $10 million in an all-scrip deal.
KEY TAKEAWAYS:
- The deal follows Sprooki securing Invigor Group as its first Australian customer in July last year.
- This resulted in Sprooki’s platform being integrated with Invigor’s Insights Visitor WiFi Analytics and Engagement product, enabling location-targeted messaging, mobile vouchers, cardless loyalty and rewards systems.
- As part of the buyout $4 million of Invigor shares will be issued to Sprooki shareholders, subject to a 12-month escrow and an additional $6 million of shares subject to performance milestones in 2017 and 2018.
- Sprooki, which is founded by two former Fairfax Media digital leaders Claire Mula and Michael Gethen, had planned on listing on the ASX via an initial public offering last year, raising $7.5 million.
Invigor Group, which is lead by iSOFT founder Gary Cohen, expects the acquisition to be earnings accretive by the 2018 financial year, adding $5 million in revenue and making the company cashflow positive, sources said.
Invigor is currently in a trading halt, but last traded at 1.5¢. Sources said Allectus Capital will join the company’s register, investing $1 million for a 12.5 per cent shareholding.
Invigor is also expected to announce former Commonwealth Bank and Westpac Bank chief information officer Bob McKinnon as chairman.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
